Dr. Christina Vallgren

CEO/Co-founder/Board of Directors - President

PhD in Applied Physics. MSc in Applied Physics and Nuclear Engineering. MBA. PMI. Staff Physicist at CERN 12+ years. Before coming to CERN, Christina earned an MSc degree in nuclear physics from Chalmers University of Technology, Sweden. In 2008 she joined CERN for a Ph.D. in applied physics and has worked there for the last 12 years. Christina was the main responsible for the LHC (Large Hadron Collider, 27 km, the world’s biggest accelerator) Beam Vacuum (the world’s biggest vacuum system) Operation and has also been the supervisor for five master students and two fellows. She is also a scientific journal referee for IEEE Transactions on Nuclear Science.


Dr. Marcus Palm

CTO/Co-founder/Board of Directors - Member

PhD in Applied Physics from Vienna & CERN. Systems and validation engineer at MedAustron, the first proton therapy facility in Austria. Responsibility: system architecture design of patient safety systems. Validation for CE-certification of the entire facility as a single medical device. Detector Physicist at CERN 13 years: expertise in development of high performance detection system. Expertise in Hadron therapy design, commissioning, CE-certificate medical devices and detector technology, data analysis.


Prof. Raymond Miralbell

CSO/Co-founder/Board of Directors - Member

Medical director at QuirónSalud, Spain, since 2019. Chairman and Associated Professor of the Radiation Oncology Division, at the University Hospital of Geneva (Switzerland) since 2006. Chairman of the Swiss Proton Users Group 2000 - 2008. Radiation oncologist trained from 1979 through 1989 in the University of Barcelona and the University of Harvard. Main research domain: Prostate cancer and breast cancer. - Imaging for radiotherapy treatment planning - Treatment precision optimization through image guided radiotherapy - Tracing of the biochemical relapse after curative surgery or radiotherapy - Prognostic value of hypoxic markers (pathological and imaging) - Quality of life studies in fragile patients on androgen deprivation - Biological modeling of prostate cancer response to irradiation and fractionation sensitivity. - Biological modeling for salvage radiotherapy after post-irradiation local failure - SBRT of prostate, breast, and oligometastatic tumors.


Maarten Schokker

Regulatory & Quality Manager

Project Manager with in depth knowledge of quality assurance systems for medical devices (ISO 13485), risk analysis (ISO 14971) and software life cycle (IEC 62304). Founder of FilFla (BE). Expertise: Successful design, development, FAT/SAT and CE-certification of an operating ion beam therapy facility. Electronic design and development.

Board of Directors 


Didier Cowling

Board of Directors - Member

Former founding CEO of Kuros, a successful biotech/medtech entrepreneur who has brought his own start-ups from idea to IPO and is currently acting as chairman of the board at several other successful Swiss start-ups.


Antonio Gambardella

Board of Directors - Member

Director of Fongit (Switzerland's premier innovation incubator), a successful entrepreneur who is currently acting as board of director at several successful start-ups.

Advisory board 


Prof. Rolf Lewensohn

Clinical Advisor

Prof. Rolf Lewensohn, M.D., Ph.D. serves as Senior Consultant at The Department of Oncology, Karolinska University Hospital. Prof. Lewensohn is the Founder of Oncopeptides AB. He has a scientific background in DNA repair and apoptotic signaling in cancer, related to cancer therapy. He published 110 scientific publications within the cancer field. He serves as a Director of Karolinska Clinical Biomics Centre. He serves as a member of the scientific board of several funding bodies e.g. the Swedish Cancer Society, The Stockholm Cancer Society and King Gustav V’s Jubilee fund. He is a Professor of Oncology at Karolinska Institutet.


Håkan Ludvigson

Business Development Advisor

Serial entrepreneur with 15+ years of experience. Currently CEO and founder of Eliq AB (a software company that helps utilities to engage their customers by providing rich energy insights tools to consumers. The company is based between Gothenburg, Sweden and London, UK.). Founder of Acosense (acoustic spectroscopy sensor technology). Expertise: Business development, market strategy


Mikael Arthursson

Business Development Advisor

Serial entrepreneur with 15+ years of experience. Currently CTO and founder of Minalyze AB. Minalyze AB was founded in 2009 in Gothenburg, Sweden and is the world leader in XRF core scanning instruments and software for visualization of geological data. The company is based both in Sweden and Australia today. Expertise: Business development in HighTech, market strategy

About Us

Founder team: Prof. Raymond Miralbell (left), Dr. Christina Vallgren (middle) and Dr. Marcus Palm (right).

Multidisciplinary team:






Investing in us:
Join us for the next generation proton therapy to fight cancer.

Please contact our CEO Christina Vallgren: